Health
Moderna RSV Vaccine Efficacy Sinks Over Time, CDC Documents Show
A researcher in the lab at the Moderna Inc. headquarters in Cambridge, Massachusetts.
Photographer: Adam Glanzman/BloombergThis article is for subscribers only.
Moderna Inc. shares sank after new data showed the efficacy of its RSV shot fell sharply in the second year and was lower than that of rival vaccines.
The results could further raise doubts over the prospects for its shot, which is already third to the market. Moderna shares fell as much as 11%, their biggest intraday decline since November.